Physician profile
Geronimo E Banayat
NPI 1376620500
$3,164.55
in general payments reported to CMS, 2019-2025
31 companies · $755 in 2025
The $755 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.99 · 2020: $154 · 2021: $213 · 2022: $441 · 2023: $593 · 2024: $938 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,260 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,260.29 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $436.15 | 2022-2025 | |
| Vifor Pharma, INC. | $249.38 | 2021-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $209.30 | 2020-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $208.71 | 2021-2024 | |
| Amgen INC. | $205.84 | 2021-2025 | Tavneos |
| Ani Pharmaceuticals, INC. | $172.66 | 2023-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $168.19 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $154.24 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Fresenius USA Marketing, INC. | $140.05 | 2019-2023 | Velphoro |
| Calliditas Therapeutics US INC. | $132.72 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $129.44 | 2022-2025 | Acthar |
| Akebia Therapeutics INC | $110.24 | 2024-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $76.89 | 2022-2025 | Jynarque |
| Lilly USA, LLC | $71.89 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Travere Therapeutics, INC. | $70.70 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $69.05 | 2022-2023 | Minimed 770g |
| Glaxosmithkline, LLC. | $68.03 | 2023-2025 | Benlysta, Jesduvroq |
| Xeris Pharmaceuticals, INC. | $66.03 | 2021-2024 | Gvoke Hypopen |
| Baxter Healthcare | $61.04 | 2019-2025 | Hillrom - Carnation Ambulatory Monitor |
| Daiichi Sankyo INC. | $58.24 | 2020-2022 | |
| Dexcom, INC. | $54.09 | 2022-2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $44.20 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $36.33 | 2019-2025 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.10 | 2024 | Xifaxan |
| Opko Pharmaceuticals, LLC | $30.37 | 2025 | Rayaldee |
| Pfizer INC. | $28.75 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.52 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.26 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $15.21 | 2023 | Crysvita |
| Amarin Pharma, INC. | $15.10 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.83 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geronimo Banayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.